SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px
Person › Details

Gundram Jung (University of Tübingen (Eberhard-Karls-Universität))

Jung, Gundram (Univ Tübingen 201205 Professor at Institute of Immunology)


Organisation Organisation University of Tübingen (Eberhard-Karls-Universität)
Product Product bispecific antibody

Baliopharm AG. (5/9/12). "Press Release: Baliopharm Signs Licensing Agreement for the Development of a Bispecific Antibody Indicated for the Treatment of Cancer and Inflammatory Diseases". Basel & Tübingen.

Baliopharm AG, which was founded as a spin-off of Celonic AG (>Celonic) last year and ApoGbR today announced the signing of a world-wide, exclusive licensing agreement for a prototypic bi-specific therapeutic antibody which has been developed by Prof. Gundram Jung, a pioneer in the area of bi-specific antibodies, at the Institute of immunology of the University Tu¨bingen. According to this agreement, Baliopharm obtains the world wide, exclusive rights on the bi-specific antibody called "Novotarg", which is developed for the treatment of specific lymphomas but also for B-cell mediated inflammatory diseases. Novotarg binds highly selective to CD20 positive normal, activated or malignant B-cells which then will be destroyed by agonistic binding to a death receptor leading to selective elimination of these cells. Due to this bi-specific design both better safety and increased efficacy is reached, as shown in preclinical experiments.

"We are very pleased that by in-licensing of Novotarg we can add a further drug candidate to our pipeline. All available data give evidence that this antibody is a further highly innovative drug, which we primarily want to develop for the treatment of multiple sclerosis", says CEO Dr. Andreas Herrmann. "Furthermore, the structure of this bi-specific antibody is highly innovative, very stable and easy to produce. That will help us to overcome the main hurdles usually associated with the production of bi-specific antibodies and we hope to enter the clinical development phase within the next 2 years."

"We highly appreciate that with Baliopharm we have found a company with international experience in the development of drugs", says Prof. Dr. Gundram Jung. "I am sure that the further development of Novotarg is in safe keeping there".

About Baliopharm AG

Baliopharm was founded in 2011 as a spin-off of Celonic AG, an internationally operating service provider in the area of contract development and manufacturing of biopharmaceuticals operating since 1998. Celonic AG has also successfully developed their own therapeutic proteins targeting immune-mediated diseases, which are now developed further by Baliopharm. The lead product "ATROSAB", a second generation TNF-antagonist with better safety and efficacy indicated for the treatment of rheumatoid arthritis, Crohn`s disease and multiple sclerosis will enter clinical development already in the second quarter of 2012.

Baliopharm GmbH, Dr. Andreas Herrmann, phone: +41-(0)61/2053911, fax: +41-(0)61/2053919

Record changed: 2017-04-09


Picture [LSE] – The Business Web Portal 600x60px

More documents for Gundram Jung

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [LSUS] – The Business Web Portal 600x60px

» top